

RIAN J. DICKSTEIN, M.D.

150 Rugby Road
Arnold, MD 21012
rdickstein@gmail.com
856-816-6460

EMPLOYMENT

Chesapeake Urology (Associate Physician) 806 Landmark Drive Suite 118 Glen Burnie, MD 21061 10-760-9400 (office) 410-761-4134 (fax) rdickstein@cua.md	2012 – present
Hospital privileges University of Maryland Baltimore Washington Medical Center Saint Agnes Hospital MedStar Harbor Hospital Howard County General Hospital MedStar Southern Maryland Hospital	2012 – present 2012 – present 2012 – present 2012 – present 2014 – present
Clinical Assistant Professor Department of Surgery at the University of Maryland School of Medicine	2013 – present

EDUCATION

The University of Texas M.D. Anderson Cancer Center Houston, TX Urologic Oncology Fellowship	2010 – 2012
Boston Medical Center (Boston University) Boston, MA Urology Residency	2006 – 2010
Boston Medical Center (Boston University) Boston, MA General Surgery Internship	2005 – 2006
Robert Wood Johnson Medical School University of Medicine and Dentistry of New Jersey (UMDNJ) New Brunswick, NJ Doctor of Medicine	2001 – 2005
Rutgers University (Rutgers College) New Brunswick, NJ Bachelor of Arts Major - Molecular Biology and Biochemistry Minor - Economics	1997 – 2001

CERTIFICATION & LICENSING

Diplomate of the American Board of Urology	2014 – present
State of Maryland Medical License	2012 – present
Qualifying (Part 1) Examination of The American Board of Urology – pass	2010
State of Texas Medical License	2010 – 2012

HONORS & AWARDS

Cancer Liaison Physician for the Tate Cancer Center at The University of Maryland Baltimore Washington Medical Center	2015 – present
The University of Maryland Baltimore Washington Medical Center “Top Doc”	2013
2011 Genitourinary Cancers Symposium Merit Award at the annual meeting	2011
2008 - 2009 Editor's Award of Excellence for an Original Study from <i>Urotoday Int J.</i>	2009
First Place Winner of the Max K. Willscher Resident Research Award Competition at the NE AUA (New England Section of American Urologic Association)	2009
SMSNA (Sexual Medicine Society of North America) Scholars in Sexuality Research Grant	2008
Graduation with Distinction in Research from Robert Wood Johnson Medical School	2005
Alpha Omega Alpha (AOA) Honor Medical Society – inducted as a 3 rd year medical student	2004 – 2005
Four year full tuition scholarship to Robert Wood Johnson Medical School (The Foundation of UMDNJ Scholars)	2001 – 2005
Summa Cum Laude at Rutgers University	2001
Rutgers College General Honors Program	1998 – 2001
Rutgers University chapter of Gamma Sigma Alpha Fraternal Honor Society	2000 – 2001
Rutgers University chapter of Golden Key Honor Society	1999 – 2001
CRLA (College Reading & Learning Association) certified tutor at the Rutgers University LRC (Learning Resource Center)	1999 – 2001
Rutgers University chapter of Phi Eta Sigma Freshman Honor Society	1998 – 2001

PEER-REVIEWED PUBLICATIONS

Kamat AM, Willis DL, **Dickstein RJ**, Anderson R, Noguera-Gonzalez G, Katz RL, Wu X, Barton Grossman H, Dinney CP. Novel fluorescence in situ hybridization-based definition of bacille Calmette Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJUI. Epub ahead of print, 2015

Dickstein RJ, Munsell MF, Pagliaro LC, Pettaway CP. Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. BJUI. Epub ahead of print, 2014.

Willis DL, Fernandez MI, **Dickstein RJ**, Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA, Grossman HB, Dinney CP, Kamat AK. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 193(1): 1-6, 2015.

Culp SH, **Dickstein RJ**, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 191(1): 40-47, 2013.

Dickstein RJ, Ng CS, Dinney CP, Kamat AK. Accuracy of Computed Tomography for Identifying Locally Advanced Disease in Patients with Muscle-Invasive Bladder Cancer. *UroToday Int J.* 6(5), 2013.

Dickstein RJ, Nitti G, Dinney CP, Davies BR, Kamat AM, McConkey DJ. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. *Cancer Biology & Therapy.* 13(13): 1325-28, 2012.

Lee EK, Herr HW, **Dickstein RJ**, Kassouf W, Munsell MF, Grossman HB, Dinney CP, Kamat AK. Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. 110(11b): E590-E595, 2012.

Kamat AM, **Dickstein RJ**, Messetti F, Anderson R, Pretzsch SM, Noguera Gonzalez G, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP. Use of Fluorescence in situ Hybridization to Predict Patient Responses to BCG Therapy for Bladder Cancer: Results of a Prospective Trial. *J Urol.* 187(3): 862-7, 2012.

Kreshover JE, **Dickstein RJ**, Rowe C, Babayan RK, Wang DS. Predictors for Negative Ureteroscopy in the Management of Upper Urinary Tract Stone Disease. *Urology.* 78(4): 748-752, 2011.

Chiong E, Lee I-L, Dadbin A, Sabichi AL, Harris L, Urbauer D, McConkey D, **Dickstein RJ**, Cheng T, Grossman HB. Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells. *Clin Cancer Res.* 17(9): 2863-73, 2011.

Dickstein R, Kreshover J, Babayan R, Wang D. Is a Safety Wire Necessary During Routine Flexible Ureteroscopy? *J Endourol.* 24(10): 1589-1592, 2010.

Dickstein RJ, Uberoi J, Munarriz R. Severe, Disabling, and/or Chronic Penile Pain Associated with Peyronie's Disease: Management with non-intralesional Administration of Steroids. *J Androl.* 31: 445-449, 2010.

Daniels AB, Worth RG, **Dickstein RJ**, Dickstein JS, Kim-Han T-H, Kim M-K, Schreiber AD. Analysis of FcγRIIA Cytoplasmic Tail Requirements in Signaling for Serotonin Secretion: Evidence for an ITAM-dependent, PI3K-dependent Pathway. *Scan J of Immunol.* 71(4): 232-239, 2010.

Minetti CA, Remeta DP, **Dickstein R**, Breslauer KJ. Energetic Signatures of Single Base Bulges: Thermodynamic Consequences and Biological Implications. *Nucleic Acids Res.* 38(1): 97-116, 2009.

Dickstein RJ, Baker EH, Siroky MB. Outcome of Patients with Abnormal Upper Tract Cytology and Negative Initial Workup. *UroToday Int J.* 2(6), 2009.

Eaton SH, **Dickstein RJ**, Wiygul JB. Novel use of the Gigli saw for management of penile entrapment. *J Sex Med.* 6:595-597, 2009.

Dickstein RJ, Barone JG, Liao JG, Burd RS. The Effect of Surgeon Volume and Hospital Characteristics on In-Hospital Outcome after Ureteral Implantation in Children. *Pediatr Surg Int.* 22(5):417-421, 2006.

Worth RG, Kim MK, Jones BA, Daniels AB, **Dickstein R**, Hunter S, Chein P, Schreiber AD. Differing Structural Requirements for FcγRIIA-Mediated Signaling Events. *Allergy Clin Immunol Int: J World Allergy Org.* Supplement 2, 2003.

REVIEW ARTICLES

Dickstein RJ, Kamat AM. Contemporary Management of Locally Invasive Bladder Cancer. *Oncology.* 25(14): 1396-405, 2011.

Lee EK, **Dickstein RJ**, Kamat AM. Imaging of Urothelial Cancers: What the Urologist Needs to Know. *AJR.* 196(6): 1249-54, 2011.

BOOK CHAPTERS

Dickstein RJ, Shetty G, Meistrich ML. (2013). In Mulhall JP, Applegarth LD, Oates RD, Schlegel PN (Eds.), Application of Spermatogenesis Suppression Therapies for Fertility Preservation (pp.) *Fertility Preservation in Male Cancer Patients*. Cambridge University Press.

PRESENTATIONS

Dickstein RJ, McCoy JA, Culp SH, Munsell MF, Pagliaro LC, Pettaway CA. Pre-operative Chemotherapy for Regionally Advanced Squamous Carcinoma of the Penis: The M.D. Anderson Cancer Center Experience. Podium presentation at the 2012 AUA annual meeting.

Dickstein R, Grossman HB, Pretzsch S, Karam J, Dinney C, Kamat A. Outcomes of Patients Who Fit Criteria for Radiation Therapy but Elect to Undergo Radical Cystectomy. Podium presentation at the 2011 South Central Section AUA annual meeting.

Kamat A, **Dickstein R**, Messetti F, Anderson R, Pretzsch S, Noguera-Gonzalez G, Katz R, Khanna A, Grossman HB, Dinney C. Updated Results from a Prospective Clinical Trial to Study the Utility of FISH in Predicting Response to BCG Therapy for Bladder Cancer. Podium presentation at the 2011 South Central Section AUA annual meeting.

Dickstein RJ, Jinesh GG, Chunduru S, Kamat AM. Potential Role of Smac Mimetics as an Adjunct in BCG Failure Patients with Non-Muscle Invasive Bladder Cancer. Poster presentation at the 2011 AUA meeting.

Dickstein RJ, Grossman HB, Pretzsch SM, Karam JA, Millikan RE, Dinney CP, Kamat AM. Can We Reliably Identify Patients for Radical Cystectomy Without Neoadjuvant Chemotherapy? *J Clin Oncol* 29: 2011 (suppl 7; abstr 258).

Dickstein RJ, Grossman HB, Pretzsch SM, Karam JA, Millikan RE, Dinney CP, Kamat AM. Can We Reliably Identify Patients for Radical Cystectomy Without Neoadjuvant Chemotherapy? Poster presentation at the 2010 SUO annual meeting.

Dickstein RJ, Weinberg AC, Wang DS, Babayan RK. Management of a Large Median Lobe during Robot Assisted Radical Prostatectomy. Video presentation at the 2009 New England section AUA annual meeting.

Dickstein RJ, Uberoi J, Munarriz R. Severe, Disabling, and/or Chronic Penile Pain Associated with Peyronie's Disease: Management with non-intralesional Administration of Steroids. Podium presentation at the 2009 New England section AUA annual meeting.

Dickstein RJ, Drzewiecki BA, Baker EH, Siroky MB. Outcome of Patients with Abnormal Upper Tract Cytology and Negative Initial Work Up. Podium presentation at the 2009 AUA annual meeting.

Dickstein RJ, Belletete BA, Baker EH, Siroky MB. Outcome of Patients with Abnormal Upper Tract Cytology and Negative Initial Work Up. Poster presentation at the 2008 55th annual meeting of the MACAS (Massachusetts Chapter of the American College of Surgeons).

Dickstein RJ, Weinberg AC, Ng L. Anterior Repair Using Perigee™ - A Transobturator Anterior Prolapse Repair System. Surgical technique video presentation at the 2008 New England section AUA annual meeting.

ABSTRACTS

Williams SB, Fernandez M, Willis DL, Slack R, Siefker-Radtke AO, Navai N, **Dickstein RJ**, Guo C, Czerniak B, McConkey DJ, Parik S, Pisters LL, Shah JB, Grossman HB, Dinney CP, Kamat AK. Risk group stratification in patients with micropapillary bladder cancer treated with radical cystectomy and/or neoadjuvant chemotherapy. To be presented at the 2015 Genitourinary Cancers Symposium.

Willis D, Fernandez M, Guo C, Czerniak B, **Dickstein R**, Parikh S, Pisters L, Grossman HB, Dinney C, Kamat A. Does the extent of micropapillary component impact clinical outcomes. *J Urol.* 185(S): e772, 2013.

Willis D, Fernandez M, **Dickstein R**, Parikh S, Shah J, Pisters L, Guo C, Czerniak B, Grossman HB, Dinney, C, Kamat A. Management of cT1 micropapillary bladder cancer. *J Urol.* 185(S): e701-702, 2013.

Fernandez M, Willis D, Slack R, **Dickstein R**, Parikh S, Siefker-Radtke A, Guo C, Czerniak B, Shah J, Pisters L, Grossman HB, Dinney C, Kamat, A. Prognostic significance of p0 stage in patients with micropapillary bladder cancer undergoing radical cystectomy. *J Urol.* 185(S): e215-216, 2013.

Fernandez M, Willis D, Slack R, **Dickstein R**, Parikh S, Siefker-Radtke A, Guo C, Czerniak B, Shah J, Pisters L, Grossman HB, Dinney C, Kamat A. Clinical outcomes of patients with micropapillary bladder cancer treated with neoadjuvant therapy and/or radical cystectomy. *J Urol.* 185(S): e214-215, 2013.

Willis DL, Lee EK, **Dickstein RJ**, Anderson R, Pretzsch SM, Noguerras-Gonzalez GM, Grossman HB, Dinney CP, Kamat AM. Novel definition of BCG failure to enhance recruitment into clinical trials. Poster presentation and abstract # 246 at the 2013 Genitourinary Cancers Symposium annual meeting.

Willis DL, Fernandez MI, **Dickstein RJ**, Parikh S, Shah JB, Pisters LL, Guo CC, Czerniak BA, Grossman HB, Dinney CP, Kamat AM. Management of cT1 micropapillary bladder cancer. Poster presentation and abstract # 308 at the 2013 Genitourinary Cancers Symposium annual meeting.

Willis DL, Fernandez MI, **Dickstein RJ**, Guo CC, Czerniak BA, Parikh S, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Clinical outcomes in focal versus extensive micropapillary bladder cancer at the time of diagnostic transurethral resection. Poster presentation and abstract # 317 at the 2013 Genitourinary Cancers Symposium annual meeting.

Willis DL, Fernandez MI, Millikan RE, **Dickstein RJ**, Parikh S, Siefker-Radtke AO, Guo CC, Czerniak BA, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Outcome of patients with micropapillary bladder cancer treated with neoadjuvant therapy and radical cystectomy. Poster presentation and abstract # 318 at the 2013 Genitourinary Cancers Symposium annual meeting.

Fernandez, MI, Willis DL, Millikan RE, **Dickstein RJ**, Parikh S, Siefker-Radtke AO, Guo CC, Czerniak BA, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Outcome of patients with micropapillary bladder cancer treated with neoadjuvant therapy and radical cystectomy. Poster presentation at the 2012 SUO annual meeting

Culp S, **Dickstein R**, Pretzsch S, Navai N, Wszolek M, Siefker-Radtke A, Kamat A, Dinney C. Refining patient selection for neoadjuvant chemotherapy prior to radical cystectomy. Poster presentation at the 2012 AUA annual meeting.

Kamat A, Lee E, Messetti F, **Dickstein R**, Anderson R, Pretzsch S, Noguera-Gonzalez G, Katz R, Grossman HB, Dinney C. Novel Definition of BCG Failure to Enhance Recruitment into Clinical Trials. Poster presentation at the 2011 South Central Section AUA annual meeting.

Dickstein RJ, Nabhani JA, Kreshover JE, Babayan RK, Katz MH, Gignac GA. Presentation of Patients with Metastatic Prostate Cancer in the Post-PSA Era. Podium presentation at the 2010 New England section AUA annual meeting.

Dickstein RJ, Rowe CK, Kreshover JE, Babayan RK, Katz MH. PSA screening in Patients with de novo Metastatic Prostate Cancer. Poster presentation at the 2010 New England section AUA annual meeting.

Kreshover JE, **Dickstein RJ**, Rowe C, Babayan RK, Wang DS. Predictors for Negative Ureteroscopy in the Management of Upper Urinary Tract Stone Disease. Podium presentation at the 2010 AUA annual meeting.

Silva Waissbluth A, Minillo B, Ganick S, Penna F, **Dickstein R**, Nguyen H. Evaluation of Pyelo-ureteral Anastomotic Viability Using Fluorescent Imaging to Prevent Postoperative Failures. Presented at the 1st World Congress of Pediatric Urology: 2010 Annual Meeting.

Dickstein RJ, Nabhani JA, Kreshover JE, Katz MH, Gignac GA. Presentation of patients with metastatic prostate cancer in the post-PSA era. *J Clin Oncol.* 28:suppl e15064, 2010.

Dickstein RJ, Ganick SJ, Geltzeiler MN, Babayan RK, Wang DS. Laparoscopic Partial Nephrectomy at Boston Medical Center: A Single Surgeon's Experience and Outcomes. *J Endourol.* 23(1):VP1-06, 2009.

Dickstein RJ, Harnisch B, Babayan RK, Wang DS. Is a Safety Wire Necessary During Routine Flexible Ureteroscopy? *J Endourol.* 23(1):VP9-03, 2009.

Dickstein RJ, Manger JP, Babayan RK, Wang DS. Predictors for Negative Ureteroscopy in the Management of Upper Urinary Tract Stone Disease. *J Endourol.* 23(1):MP8-09, 2009.

Dickstein RJ, Weinberg AC, Wang DS, Babayan RK. Management of a Large Median Lobe during Robot Assisted Radical Prostatectomy. *J Endourol.* 23(1):VS14-04, 2009.

Penna FJ, Silva AD, **Dickstein RJ**, Nguyen HT. Intraoperative Fluorescent Molecular Imaging of Vascular Perfusion in Minimally-Invasive Repair of Ureteropelvic Junction Obstruction: an Evaluation of Pyelo-ureteral Anastomotic Viability Using Indocyanine Green Fluorescence in a Pig Model. Podium presentation at the 2009 New England section AUA annual meeting.

Dickstein RJ, Kreshover JE, Milose JC, Gignac GA. Metastatic Prostate Cancer at Diagnosis: Clinical Presentation in the Post-PSA Era. *J Clin Onc.* 27:e16159, 2009.

Chen CF, Kim MK, Pan XQ, Patel M, **Dickstein R**, Schreiber AD. Effect of Arrestins on Fc γ Receptor-Mediated Phagocytosis. *Blood.* 94(10):426A, 1999.

Worth RG, Daniels AB, **Dickstein R**, Kim MK, Schreiber AD. A Molecular Model for Studying Fc γ RIIA-Mediated Secretion. *FASEB.* 15(4):A685, 2001.

Dickstein R. Binding of anti-GBM Antibodies to Ectopically Expressed Proteins in the Liver. *Blood: Journal of the American Society of Hematology.* 100(11), 2002.

LABORATORY-BASED RESEARCH EXPERIENCE

PI3K/AKT/mTOR signaling pathway in bladder cancer. 2010 – 2011
The University of Texas M.D. Anderson Cancer Center, Urology Department
PI – David McConkey/Colin Dinney/Ashish Kamat

American Society of Hematology (ASH) summer research fellowship 1999 – 2002
University of Pennsylvania, Hematology/Oncology Department
PI – Dr. Alan Schreiber

Impact of Lesions on DNA Duplex Properties and Recognition: Consequences of Base 2000 – 2001
Bulges and Sequence Context on Duplex Energetics and Conformation.
Rutgers University, Chemistry Department
Henry Rutgers Honors Thesis
PI – Dr. Kenneth Breslauer

CLINICAL RESEARCH WITH HUMAN PARTICIPANTS

Sub-Investigator (Protocol # PHI-HEOR-01-15) – A Prospective, Observational Study of the Clinical Decision Impact of the Prostate Health Index (*phi*) Test in a Urology Practice Setting.

Sub-Investigator – In-office user evaluation of the Cx bladder test in the primary detection and initial diagnosis of bladder cancer.

Sub-Investigator (Protocol # 14-001) – Genomic Markers in Transitional Cell Cancer of the Bladder, Renal Pelvis and Ureter: Sample Acquisition for Methods Development and Discovery.

Sub-Investigator (Protocol # 09-023) – A Prospective Multicenter Observational trial to Assess Persistence on Active Surveillance When Using the Oncotype DX Prostate Cancer Assay.

Sub-Investigator (NCT01939184) – Assess Safety & Efficacy of WC3055 in Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Sub-Investigator (NCT01945580) – A Prospective, Non-Randomized, Parallel Cohort, Multi-Center Study of Xenform vs. Native Tissue for the Treatment of Women with Anterior/Apical Pelvic Organ Prolapse.

Sub-Investigator (NCT01438775) – Clinical Safety Evaluation of Re-Injection of NX-1207 For the treatment of BPH: Two Doses 1-8 years apart.

Sub-Investigator (NCT02045862) – A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder Protocol for Phase 3 Study of Solifenacin Succinate and Mirabegron.

Principal Investigator (NCT02003924) – A Multinational, Phase 3, Randomized, Double-Blind Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER).

CURRENT MEMBERSHIPS

AUA (American Urologic Association)	2006 – present
SRS (Society of Robotic Surgery)	2012 – present
AMA (American Medical Association)	2012 – present
MedChi (The Maryland State Medical Society)	2012 – present
GUMDROP (GenitoUrinary MultiDisciplinary D.C. Regional Oncology Project)	2013 – present
SUO (Society of Urology Oncology) – Active Member	2013 – present
ACS (American College of Surgeons) – Associate Fellow	2015 – present

EDITORIAL ACTIVITIES

Reviewer <i>J Urol</i>	2010 – 2012
Reviewer <i>F1000 (Faculty of 1000 Post-Publication Peer Review)</i>	2010 – 2012
Reviewer <i>Carcinogenesis</i>	2010 – 2012
Reviewer <i>Eur Urol</i>	2010 – 2012
Reviewer <i>BJU International</i>	2010 – present
Reviewer <i>Urologic Oncology: Seminars and Original Investigations</i>	2010 – present

CONSULTING

Watson Pharmaceuticals – intermittent ADT for prostate cancer	December 2012
Endo Pharmaceuticals – Valstar Advisory Board	March 2014
Pacific Edge Diagnostics – Cx Bladder Advisory Board	February 2015